Boerstra Brittany A, Boenink Rianne, Astley Megan E, Bonthuis Marjolein, Abd ElHafeez Samar, Arribas Monzón Federico, Åsberg Anders, Beckerman Pazit, Bell Samira, Cases Amenós Aleix, Castro de la Nuez Pablo, Ten Dam Marc A G J, Debska-Slizien Alicja, Gjorgjievski Nikola, Giudotti Rebecca, Helve Jaakko, Hommel Kristine, Idrizi Alma, Indriðason Ólafur S, Jarraya Faiçal, Kerschbaum Julia, Komissarov Kirill S, Kozliuk Nadiia, Kravljaca Milica, Lassalle Mathilde, De Meester Johan M, Ots-Rosenberg Mai, Plummer Zoe, Radunovic Danilo, Razvazhaieva Olena, Resic Halima, Rodríguez Arévalo Olga Lucía, Santiuste de Pablos Carmen, Seyahi Nurhan, Slon-Roblero María Fernanda, Stendahl Maria, Tolaj-Avdiu Miloreta, Trujillo-Alemán Sara, Ziedina Ieva, Ziginskiene Edita, Ortiz Alberto, Jager Kitty J, Stel Vianda S, Kramer Anneke
Department of Medical Informatics, University of Amsterdam, ERA Registry, Amsterdam UMC, Amsterdam, The Netherlands.
Amsterdam Public Health, Health Behaviours & Chronic Diseases, Amsterdam, The Netherlands.
Clin Kidney J. 2023 Nov 15;17(2):sfad281. doi: 10.1093/ckj/sfad281. eCollection 2024 Feb.
The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with end-stage kidney disease (ESKD). This paper is a summary of the ERA Registry Annual Report 2021, including a comparison across treatment modalities.
Data was collected from 54 national and regional registries from 36 countries, of which 35 registries from 18 countries contributed individual patient data and 19 registries from 19 countries contributed aggregated data. Using this data, incidence and prevalence of KRT, kidney transplantation rates, survival probabilities and expected remaining lifetimes were calculated.
In 2021, 533.2 million people in the general population were covered by the ERA Registry. The incidence of KRT was 145 per million population (pmp). In incident patients, 55% were 65 years or older, 64% were male, and the most common primary renal disease (PRD) was diabetes (22%). The prevalence of KRT was 1040 pmp. In prevalent patients, 47% were 65 years or older, 62% were male, and the most common PRDs were diabetes and glomerulonephritis/sclerosis (both 16%). On 31 December 2021, 56% of patients received haemodialysis, 5% received peritoneal dialysis, and 39% were living with a functioning graft. The kidney transplantation rate in 2021 was 37 pmp, a majority coming from deceased donors (66%). For patients initiating KRT between 2012-2016, 5-year survival probability was 52%. Compared to the general population, life expectancy was 65% and 68% shorter for males and females receiving dialysis, and 40% and 43% shorter for males and females living with a functioning graft.
欧洲肾脏协会（ERA）登记处收集终末期肾病（ESKD）患者肾脏替代治疗（KRT）的数据。本文是ERA登记处2021年年报的总结，包括不同治疗方式的比较。
数据收集自36个国家的54个国家和地区登记处，其中18个国家的35个登记处提供了个体患者数据，19个国家的19个登记处提供了汇总数据。利用这些数据，计算了KRT的发病率和患病率、肾脏移植率、生存概率和预期剩余寿命。
2021年，ERA登记处覆盖了普通人群中的5.332亿人。KRT的发病率为每百万人口145例（pmp）。在新发病例中，55%为65岁及以上，64%为男性，最常见的原发性肾脏疾病（PRD）是糖尿病（22%）。KRT的患病率为1040 pmp。在现患病例中，47%为65岁及以上，62%为男性，最常见的PRD是糖尿病和肾小球肾炎/硬化症（均为16%）。2021年12月31日，56%的患者接受血液透析，5%接受腹膜透析，39%拥有功能正常的移植肾。2021年的肾脏移植率为每百万人口37例，大多数来自 deceased donors（66%）。对于2012 - 2016年间开始KRT的患者，5年生存概率为52%。与普通人群相比，接受透析的男性和女性预期寿命分别缩短65%和68%，拥有功能正常移植肾的男性和女性预期寿命分别缩短40%和43%。 （注：“deceased donors”未找到准确对应中文，可根据实际情况调整，比如“已故捐赠者” ）
